• An estimated 91% of U.S. adults (91%) say either that marijuana should be legal for medical and recreational use or that it should be legal for medical use only
• While cannabis remains an illegal substance federally, a growing number of states have legalized the substance
• An emerging leader in the U.S. cannabis marketplace, NUGS’ vision is to acquire, scale assets in the legal cannabis market

A vast majority of adults in the United States say that marijuana should be legal for either medical and recreational use or at least for medical use, according to a recent Pew Research Center report (https://ibn.fm/zqnb9). Companies such as Cannabis Strategic Ventures (OTC: NUGS) look to those numbers in anticipation of a promising future. “As more states, including Virginia and New York, continue to legalize marijuana, an overwhelming share of U.S. adults (91%) say either that marijuana should be legal for medical and recreational use (60%) or that it should be legal for medical use only (31%),” the Power Research Center article notes. “Fewer than one in ten (8%) say marijuana should not be legal for use by adults.” While cannabis remains an illegal substance federally, a growing number of states have legalized the substance. “Lawmakers across the U.S. proved again in 2021 that marijuana reform will continue to advance on the state level despite the recalcitrance of Congress to end federal prohibition,” a “Marijuana Moment” article states (https://ibn.fm/fMloj). “As more eyes turn to 2022 legislative sessions, a report from NORML that was released on Monday details advocates’ progress on the cannabis front this year in more than 25 states, where over 50 pieces of marijuana reform legislation were enacted. Most notably, legislatures and governors in five states enacted recreational legalization — a notable trend given that the reform has historically been decided by voters as ballot initiatives,” the article continued. “But 2021 has also seen more modest policy changes related to medical cannabis, decriminalization and social equity. ‘State lawmakers took unprecedented steps this year to repeal marijuana prohibition laws and to provide relief to those millions of Americans who have suffered as a result of them,’ NORML Deputy Director Paul Armentano said.” As growing numbers of Americans of across a variety of ages and political affiliations support the legalization of cannabis, companies that are establishing a strong foothold in the industry stand to benefit. Cannabis Strategic Ventures is one of those companies. An emerging leader in the U.S. cannabis marketplace as a publicly traded cannabis cultivator, the company’s vision is to acquire and scale assets in the legal cannabis market while achieving efficiencies through economies of scale and vertical integration. As part of that vision, Cannabis Strategic Ventures owns NUGS Farm North, a six-acre cannabis farm in Northern California. In addition, the company is committed to taking other steps to strengthen its position in the growing market, including working toward taking operational control of each license. The company also recently celebrated the opening of its cannabis dispensary and is looking to deploy another license to establish an indoor cultivation facility with capacity to produce two to three pounds of premium exotic cannabis flower per light per harvest. For more information, visit the company’s website at www.CannabisStrategic.com. NOTE TO INVESTORS: The latest news and updates relating to NUGS are available in the company’s newsroom at http://ibn.fm/NUGS

• The strategic move to incorporate SRAX is designed to bring investor visibility for all of the upcoming events that Lexaria has planned for 2022
• Lexaria’s patented DehydraTECH(TM) technology is poised to leverage multiple industries – notably the CBD industry, with a projected value of $108.8 billion by 2027
• The advertising and media contract will allow SRAX to engage and manage social media companies for the creation and distribution of advertising materials promoting Lexaria Bioscience

Lexaria Bioscience (NASDAQ: LEXX), an innovator of drug delivery platforms, announced that it will kick off 2022 with an advertising and media agreement with SRAX (NASDAQ: SRAX) for media buys and digital marketing. The announcement is the first in a long line of plans that the company has made for the new year, a year anticipated to be the busiest yet for the company. The strategic move to bring on SRAX will help Lexaria increase its visibility to the investor community, enhancing the company’s exposure across all networks (https://ibn.fm/nBGuM). Lexaria’s advertising and media contract with SRAX allows the latter to engage and manage media companies to create and distribute advertising materials made available online. SRAX will control when these communications are released to the online customer audience. As a financial technology company, SRAX uses cutting-edge algorithms to aid in maximizing engagement. Chris Bunka, CEO of Lexaria, commented on the advertising and media contract, saying that his company was pleased to be working with SRAX to inform and engage a broad investor community in a year-long media outreach campaign. “Lexaria has made tremendous progress during 2021, and we expect even more significant advancement in 2022 and are pursuing the broadest possible investor involvement to ensure that Lexaria’s achievements are communicated to all investors,” Bunka added. The new year promises to be a busy one for the company, with several projects set to be initiated or conducted over the next 12 months:

• a six-week human clinical trial to study hypertension and evaluate Lexaria’s DehydraTECH-CBD for the potential hypertension relief
• a potentially industry-changing oral nicotine human study which will include both subjective evaluation and objective blood measurements to demonstrate the superiority of DehydraTECH-nicotine in comparison to leading industry products
• animal studies designed to evaluate DehydraTECH-CBD for seizure relief and a comparison against the only FDA-approved pharmaceutical in use for treatment against certain seizure disorders
• the company expects to complete its pre-IND meeting with the FDA during the new year and proceed with the IND application process, registering the clinical trial testing of DehydraTECH-CBD for hypertension

Lexaria’s patented DehydraTECH technology is designed to deliver fat-soluble drugs and other active pharmaceutical ingredients, increasing effectiveness and improving absorption into the bloodstream. By changing the way these pharmaceuticals are absorbed, Lexaria is speeding up the delivery and subsequent effects of the drug, increasing brain absorption, reducing drug administration costs, improving the potency of the drug, and even masking unwanted tastes. The company is positioned to leverage its technology to gain access and cement its position in several markets worth billions in forecasted market value. For example, in 2020, the cannabidiol (CBD) market size surpassed $7.1 billion and is estimated to grow at a CAGR of 35%, topping $108.8 billion by 2027. Listed drivers for growth include an increase in medical applications for CBD (much like Lexaria’s DehydraTECH technology), increased product adaptations, increased retail sales, and more (https://ibn.fm/Am3bk). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Meeting takes company a step closer to advancing its lead investigational candidate CYB003 into clinical development
• CYB003 is designed for the treatment of two significant conditions: major depressive disorder (“MDD”) and alcohol use disorder (“AUD”)
• CEO notes that CYB003 has the potential to achieve better patient outcomes

The coming year holds significant promise for Cybin (NEO: CYBN) (NYSE American: CYBN) for numerous reasons. The biopharmaceutical company has seen significant success in the execution of its strategic focus on progressing psychedelics to therapeutics, including its recent announcement that company representatives will hold a scientific advice meeting with the UK Medical and Healthcare Products Regulatory Agency (“MHRA”) early in 2022 (https://ibn.fm/MgASx). The meeting, which is scheduled to take place in Q1, takes the company a step closer to advancing its lead investigational candidate CYB003 into clinical development for the treatment of two significant conditions: major depressive disorder (“MDD”) and alcohol use disorder (“AUD”). CYB003 is specifically formulated to address the shortcomings of existing treatments while retaining the therapeutic benefits of oral psilocybin, the company noted. “We believe that CYB003 has the potential to achieve better patient outcomes, including less variability, faster onset of action, shorter duration of effect, and improved brain penetration,” said Cybin CEO Doug Drysdale. “As a society, we need to prioritize the treatment of mental health, and Cybin is committed to taking these next important steps toward progressing psychedelics to therapeutics.” The meeting with the MHRA comes after the company announced preclinical data for CYB003 indicating that the compound demonstrated a 50% reduction in variability compared to oral psilocybin, which could mean more accurate dosing. The data also demonstrated a 50% reduction in dose compared to oral psilocybin, which potentially means that common side effects could be reduced. In addition, the data showed a 50% shorter time to onset and nearly double brain penetration, both indicators of potential benefits to developing CYB003 as an effective treatment for MDD and AUD. “Encouraged by positive preclinical findings that demonstrated the advantages of our novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health, we are moving rapidly to progress CYB003 toward clinical development,” said Drysdale. “We are looking forward to engaging with the MHRA to determine next steps for our clinical development path evaluating CYB003 for the treatment of MDD and AUD in the UK.” In addition to its upcoming meeting with MHRA, Cybin has announced plans to file a clinical trial application with the agency in 2022. A leading ethical biopharmaceutical company, Cybin is working with a network of world-class partners and internationally recognized scientists to create safe and effective therapeutics for patients to address a multitude of mental health issues. The company operates in the United States, the United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Besides the monthly contest prizes, artists who promote three of their streams on Instagram and tag @fanpasslive have the opportunity to earn an additional $30 this month
• Fan Pass Live’s Winter Merchandise Collection is now available for purchase on the website – the merchandise is Fan Pass branded and features items like hoodies, socks, beanies, sweatpants, and more
• Fan Pass Live Artist Pro subscriptions are available for $8.99 per month and provide extra perks for artists on the platform

Mobile technology and marketing company Friendable Inc.’s (OTC: FDBL) Fan Pass Live platform has released its January contest for artists. The contest is titled “Win 2 Ways in January!” and is designed to reward artists who earn the most tips from their fans during streaming done throughout the month of January. In addition to the first-place prize of $500, the second-place prize of $250, and the third-place prize of $150, artists keep 100% of the tips they earn during their streams. As in previous months, the artists who promote at least three streams on Instagram and tag @fanpasslive win an additional $30. The Winter Collection of Fan Pass branded merchandise has also landed on the company’s online shop (https://ibn.fm/jwt6v). The Winter Collection will only be around for a limited time and features apparel such as hoodies, zip-up hoodies, denim t-shirt, zip-up piped fleece jackets, beanies, sweatpants, socks, and more. Some of these items are on sale for a limited time. Fan Pass Live’s merchandise section also makes it possible for fans to find merchandise from their favorite artists. One of the artists whose merchandise can be found in the Fan Pass Live shop is Brazy Luca (@itsbrazyluca), who took to Instagram to express appreciation for the platform. “This platform is really awesome, and communication from the staff is amazing! I love the fact that I am interacting with real people that really understand the true craft and realization of each artist,” Brazy Luca said in a post (https://ibn.fm/48NKI). Fan Pass Live’s staff has extensive music industry experience, starting from the top: co-founders (and brothers) Robert A. Rositano Jr. and Dean Rositano have spent over 25 years in the industry, working with various artists and helping them expand their revenue generating opportunities while giving fans what they want as well. One of Fan Pass Live’s most recent offerings designed to help artists earn more is Artist Pro, a subscription-based service that enables artists to give a more intimate experience to their fans. For only $8.99, Artist Pro includes:

• A VIP all-access subscription to view exclusive content on Fan Pass
• Activation of your individual merch store with a custom design
• Access to advanced analytics
• Your scheduled events promoted on Fan Pass platforms

Fan Pass Live’s artists who purchase any Pro Services can gain more control over their careers, from self-promotion to performances and revenue generation. Pro Services vary in price but offer services with three different tiers for logo, merchandise, and marketing designs. There is also a shop where artists can find all the equipment and accessories they need to put on the show of a lifetime. From acoustic foam panels to selfie-rings and DJ mixers to an entire recording bundle – Fan Pass Live’s shop hooks up artists with the best equipment to put on their livestreams. “We continue to build on each of our successes and learn more every single day from our artists, and that’s what it’s all about. Support is more than something you say, it’s really about what you do,” Robert A. Rositano Jr. said in a recent interview with the Los Angeles Tribune (https://ibn.fm/0Lqbi). “Our team prides itself on being the family all artists need, one in which the relationship goes both ways. It’s not about control; we should succeed together, which is what we are building here with Fan Pass Live.” For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Zacks Investment Research recently raised its forecast for SRAX’s 4Q21 revenues to $10.05mn, representing +122.3% YoY growth
• Zacks have also upped their fiscal year 2022 revenue forecast to $42.52 million, implying +35% YoY growth
• SRAX’s implied results look even more impressive given that it will no longer be consolidating the financials of key subsidiary, BIGtoken, following the latter company’s merger with BritePool, Inc
• SRAX’s future growth trajectory is set to be dictated by investor intelligence platform, Sequire, having recently recorded its twelfth consecutive quarter of revenue growth

SRAX (NASDAQ: SRAX) a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has seen its financial performance go from strength to strength over the past year. SRAX recently reported its third quarter results on November 15th, 2021, revealing third quarter revenues of $8.3 million, a figure which was up 219% year-over-year and 8% on a quarter-over-quarter basis. Zacks Investment Research, an American independent research and investment content advisory, has recently published its forecast for the upcoming quarter, projecting SRAX to report $10.05 million in sales for the current fiscal quarter. SRAX reported sales of $4.52 million over the same quarter last year, which would imply a theoretical year over year growth rate of 122.3%. SRAX is expected to publish its fourth quarter results on Monday, April 4th, 2022 (https://ibn.fm/HnE2o). According to the analysts at Zacks Investment Research, SRAX is expected to report full year sales of $31.48 million for the current fiscal year, with current analyst estimates ranging from $31.43 million to $31.53 million. Meanwhile and for 2022, Zacks expects SRAX to report sales of $42.52 million. SRAX’s large growth trajectory looks even more impressive in light of the news that the company will no longer consolidate the financials for its former subsidiary, BIGtoken, Inc following the latter company’s merger with BritePool, Inc; both companies formally announced the completion of their merger as of December 2, 2021, with the combined entity changing its corporate name to BIGtoken, Inc. Rather, SRAX will continue to hold a BIGtoken position on their balance sheet valued at nearly $4 million, with the carrying value of the equity set to be adjusted on a quarterly basis to mark the position to market. SRAX’s future growth will be driven by Sequire, SRAX’s investor intelligence platform, with Sequire having reported 3Q21 bookings of $8.9 million with Q4 set to rise to a record $12.5 million as of date. SRAX management revealed that they were projecting a further $4 million in Sequire bookings during the fourth quarter, a target which would drive the division’s total booked revenue in Q4 to $16.5 million and extend a run which has seen Sequire report twelve consecutive quarters of revenue growth. Christopher Miglino, Founder and CEO of SRAX elaborated on the results, “Our team continues to innovate on product, sales, and marketing; and this is translating into increased revenue. We will hit the high end of our 2021 guidance and are well positioned to close out 2021 strong, with an amazing 2022 on the horizon.” SRAX’s impressive results and growth trajectory have also played a significant role in bolstering its shareholder register, with several hedge funds and other institutional investors having recently added to their stakes in the business. BlackRock Inc. raised its stake in SRAX by 3.9% during the 3rd quarter, with the asset manager now possessing 70,504 shares of the business services provider’s stock worth $377,000 after acquiring an additional 2,653 shares during the period. Northern Trust Corp raised its stake in SRAX by 16.5% during the 2nd quarter, taking its stake up to 37,199 shares of the business services provider’s stock worth $202,000 after acquiring an additional 5,267 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in SRAX by 8.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 93,283 shares of the business services provider’s stock worth $507,000 after acquiring an additional 7,400 shares during the period. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• PlantX Life Inc. is an e-commerce retailer devoted to not only selling plant products, but educating consumers about their effective use and wellness benefits
• The company has developed a weekly podcast series, YouTube channel videos and an active blog to provide information about the plant-based ecosystem
• Global thought leaders concerned about climate change are signaling the role traditional meat production plays in concerns about the planet’s environment, ranging from methane production to deforestation issues
• Concerns about effective food production and climate sustainability also point to the conflicts and wars that inevitably arise from national insecurity
• Consumers who identify themselves as vegan or largely interested in plant-based products are a rapidly growing sector of the food market, creating a need for an information hub such as that developed by PlantX Life

When world political leaders and influencers gathered for The 2021 United Nations Climate Change Conference, more commonly referred to as COP26, in October and November, concerns about how to abandon fossil fuel technologies in favor of fuels with a less-polluting, climate-sustaining footprint captured media attention. But another significant emerging concern among many of the nations is food sustainability as the earth’s climate grows hotter.

“Food security is national security,” former deputy assistant secretary of defense Matt Spence, a senior official at the National Security Council (“NSC”), stated in a recent opinion editorial for Slate that argues for the importance of adopting plant-based meats and lab-grown, animal cell-based meats as alternatives to current meat-based lifestyles (https://ibn.fm/jORZv).

“Already, countries are facing the first famines caused by climate change. While heading up Middle East policy at the Pentagon, I saw how ISIS leveraged drought and crop failures to win the support of vulnerable populations and expand its reach,” Spence stated. “Industrialized agriculture is a greater contributor to methane emissions than any other source. Meat is the top contributor to deforestation. … Per pound, conventional meat production produces more than 10 times as much air pollution and more than six times as much toxic chemicals as plant-based meat. A 2018 study suggests that replacing a chicken patty with a plant-based alternative could reduce emissions by two-thirds.”

Spence concluded that eating less industrially farmed meat will be good for the planet and help nations avoid the war and conflict that follow food pressures brought on by industrialized agriculture-caused climate change.

Plant-based lifestyle e-retailer PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) is working to position itself at the forefront of efforts to adopt a plant-based, alternative protein-based lifestyle that not only promotes nutritional health, but overall well-being through connectivity to the earth’s natural resources and efforts to sustain them. And in keeping with Spence’s observations, plant-based living could help promote national security.

PlantX Life aims to be a one-stop shopping source for plant-based products as well as for information that educates consumers about how to pursue and enjoy a plant-based lifestyle. Worldwide, an estimated 2 billion people live primarily on a meat-based diet, while an estimated 4 billion live primarily on a plant-based diet, a 2003 report for The American Journal of Clinical Nutrition noted (https://ibn.fm/hIJVn).

In the United States, a separate report found a 500 percent increase in consumers who state they are vegan between 2014 and 2017, and an 11 percent increase in retail sales of plant-based foods between 2018 and 2019 (https://ibn.fm/LuqAD).

The statistics indicate a steady market for the plant-based lifestyle, as well as a need for resources to sustain newcomers’ efforts to adopt such a lifestyle. PlantX’s educational strategy includes a weekly podcast, blog and YouTube presence that provide an abundance of tips on healthy diet choices, plant-growing wisdom and how to fit into the growing vegan community.

During the past year, the company also began employing the power of social media “micro-influencers” to advance the PlantX brand and widen the potential for plant-based wellness adoption.

“PlantX is always looking to adopt the most effective and impactful marketing strategies and leveraging the power of social media is a crucial component of our marketing efforts,” PlantX founder Sean Dollinger stated when the strategy was announced in November (https://ibn.fm/7P8Ew).

For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Best Startup Canada named BevCanna Enterprises one of the 101 Top Food and Beverage Startups and Companies in Canada
• BevCanna was also recognized as one of the Top 101 Cannabis Startups in the country
• The company has had strong growth momentum in its core business, with 3Q21 revenues rising over 1,000% year-over-year
• BevCanna signed an agreement to manufacture and white-label cannabis beverages on behalf of Averi Health Products, which will subsequently be distributed in the Canadian market

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) — a diversified health & wellness beverage and natural products company developing and manufacturing a range of alkaline, plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients — announced that it had been named as one of the 101 Top Food and Beverage Startups and Companies in Canada by Best Startup Canada, a media company that focuses on the latest innovations, breakthroughs and greatest companies across Canada (https://ibn.fm/vwGbE). Ranging from cutting-edge startups to established brands within the food and beverage sector, the companies recognized on the prestigious Top 101 list are known for both their innovation within their field as well as their exceptional growth and social impact. “It’s both an honor and a reflection of the BevCanna team’s expertise and dedication to be included within the sphere of other premier Canadian food and beverage companies, including Ritual, Goodfood, Flow Water, Chef’s Plate and David’s Tea,” noted Marcello Leone, CEO of BevCanna. “This recognition of our leadership position within both the food and beverage and the cannabis products categories validates our strategy of developing innovative, highly-customized beverage products that appeal to a range of target markets, including value, craft and premium positioning, for both our in-house brands and our white-label clients.” In addition to being selected to the 101 Top Food and Beverage list, BevCanna was also recognized as being part of the Top 101 Cannabis Startups and Companies in Canada, a list of innovators and growth companies within the Canadian cannabis industry. BevCanna Enterprises’ recent accolades come amidst a period of strong ongoing growth momentum for the company, most aptly illustrated through BevCanna’s strong third quarter earnings report, with the company revealing that it witnessed revenues rise by upwards of 1,000 percent to $1.1 million over the quarter. BevCanna Enterprises has seen its commercial prospects go from strength to strength as it worked towards broadening its product portfolio, having just entered into an agreement to manufacture and white-label cannabis beverages for Averi Health Products (https://ibn.fm/KcZfb), an emerging beverage company seeking to formulate sophisticated cocktails that replicate the flavor profile of some of the world’s most traditional and best-selling cocktails, while boasting zero alcohol content. The Averi announcement follows on from similar deals, with BevCanna signing agreements with The Tinley Beverage Company (CSE: TNU) (OTCQX: TNYBF), Keef Brands and Xebra Brand Ltd (CSE: XBRA) (OTC: XBRAF) (FSE: 9YC) over the past several months for the manufacture of its respective products for distribution within the Canadian market. To that end and to further its distribution footprint within the nation, BevCanna’s Naturo Group announced that it had finalized an agreement with leading North American wholesale distributor, United Natural Foods (NYSE: UNFI). Pursuant to the agreement, UNFI Canada will carry and distribute BevCanna’s TRACE line of products, resulting in a significant expansion of the company’s over 3,000 points of retail distribution across the country. For more information, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• Nug Avenue success provides healthy backdrop as SGMD looks ahead to opening new locations
• In addition to adding members, Nug Avenue has added new cannabis delivery technology to its format
• New delivery tech provides everything from route optimization to real-time delivery updates, saving time and money while producing higher customer satisfaction

Cannabis delivery continues to be a promising space in California — and around the country, for that matter— and the success of Sugarmade’s (OTC: SGMD) Nug Avenue firmly establishes the company as a leader in the growing sector (https://ibn.fm/IYCae). SGMD is leveraging the combination of Nug Avenue’s high performance and new delivery technology as it moves forward with expansion plans. “We have seen rapid and accelerating organic growth in customers at our initial Nug Avenue location since we opened the doors in March,” said Jimmy Chan, Sugarmade CEO. “The good news is that this trend survived reopening, with a reduction in pandemic-related measures and regulations having no impact on our growth. That provides a very healthy backdrop as we look ahead to opening new locations, upgrading our service and verticalizing our model through our own cultivation resources.” In a recent shareholder update, Chan noted that SGMD’s initial Nug Avenue hub, which is located in the Los Angeles metro area, has seen dramatic growth since opening its doors in March 2021. In fact, by the end of June 2021, it had gathered more than 10,000 unique members. That growth has only increased, reaching nearly 25,000 unique members in the company’s most recent report. In addition to adding members, SGMD’s Nug Avenue has added new cannabis delivery technology to its format. Nug Avenue now features the Onfleet last-mile delivery solution with Blaze, which is designed specifically to strengthen the company’s competitive advantage in its core delivery zone. According to the company Onfleet provides AI-based automated dispatch, automatic SMS customer notifications with accurate ETAs, real-time driver tracking, proof-of-delivery, feedback collection tools, and powerful analytics to ensure every delivery is an optimal experience. “The industry average is measured in hours when it comes to cannabis orders in the California delivery marketplace,” reported Chan, who noted that in the first month of adoption, Nug Avenue’s average delivery time decreased to 41.51 minutes, and customer satisfaction rose to 4.83 out of 5 stars on average. “We are working to shorten that window and gain an edge to drive market share gains. This technology provides everything from route optimization to real-time delivery updates, saving us time and money while producing higher customer satisfaction in the process. Given this information, SGMD’s plans to expand seem grounded in sound strategy. The company has already submitted all documentation for the opening of a second Nug Avenue location and is ready to take whatever additional action is required in order to officially open the new location. And that’s just the beginning. SGMD management is also looking for additional properties for further expansion, including outside of the LA marketplace. Expanding its Nug Avenue piece isn’t the only growth in Sugarmade’s future. The company is taking active steps toward the first planting at its subsidiary Lemon Glow, a large 640-acre outdoor cultivation sit. SGMD is waiting for the final go-ahead for the 2022 planting season. Sugarmade has set its eyes on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while also developing its in-house cannabis production capacity to verticalize operations in the space. Through a combination of organic growth and strategic acquisitions, Sugarmade is working to develop a full farm-to-door vertically integrated cannabis business. The company’s brand portfolio includes CarryOutsupplies.com, SugarRush(TM), NUG Avenue, Lemon Glow and Budcars. For more information, visit the company’s website at www.Sugarmade.com. NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SGMD

• Mydecine has partnered with Dr. Matthew Johnson and Johns Hopkins University for two upcoming trials for MYCO-001 – a psilocybin approach to smoking cessation
• The company is positioned to fill a billion-dollar hole in the industry after the leading pharmaceutical Chantix was removed from the market due to cancer risks
• Two previous psilocybin trials conducted by Dr. Johnson, show promising results for the use of psilocybin as a smoking cessation tool when paired with cognitive behavioral therapy (“CBT”)

Smoking remains among the leading public health concerns of the 21st century. The total number of tobacco-related deaths worldwide has reached six million, a figure expected to rise to eight million by 2030 (https://ibn.fm/RYhMD). Earlier this year, one of the leading smoking cessation tools prescribed by physicians, Chantix, was pulled off the market for its cancer risk, leaving a large hole in a fast-growing market rife with opportunity. Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a  biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, is in a good position to tap into the opportunities offered by this sector, which is expected to reach $63.99 billion by 2026, growing at a CAGR of 16.9% (https://ibn.fm/4ag0A). Mydecine has partnered with Dr. Matthew Johnson and Johns Hopkins University (“JHU”) to advance the company’s lead drug candidate MYCO-001 as a smoking cessation treatment. MYCO-001 is 99% pure psilocybin – a hallucinogenic alkaloid, which is often found in mushrooms. Positive clinical data has been produced assessing psilocybin and smoking cessation. In 2014, Johnson conducted a study of 15 participants that underwent cognitive behavior therapy (“CBT”) and used psilocybin. A total of 67% of the group had abstained from nicotine use at the clinical data’s 12-month mark. Again, in 2020, Johnson conducted a new smoking cessation study that showed promising results as well. This trial consisted of 100 participants who used a combination of a single dose psilocybin and CBT or the nicotine patch and CBT.  At the 12-month follow-up, the psilocybin treatment saw 59% abstaining from nicotine and 28% abstaining with the use of the patch. In 2022, Johnson will be conducting two clinical trials to assess the safety and efficacy of the Mydecine’s proprietary MYCO-001 for treating nicotine dependence. The company’s seamless phase 2/3 trial at JHU will run in conjunction with Dr. Matt Johnson’s multi-site NIDA (National Institute on Drug Abuse) grant-funded study taking place at Johns Hopkins University, New York University and University of Alabama Birmingham. The NIDA study marks the first time in 50 years the government has funded a study of a psychedelic compound for therapeutic use. To date, Mydecine is the only company sponsoring clinical trials that use psilocybin to treat nicotine dependence. At this rate, Mydecine has positioned itself to bring a safer, more effective treatment to market as early as 2024 (https://ibn.fm/5zTRm). Mydecine CEO Josh Bartch commented about upcoming trials in 2022 and discussed Johnson’s role in conducting these studies, as well as the C$5.5 million (US$4.2 million) financing the company received recently to fund its research (https://ibn.fm/pkCqK). “I would like to thank our incredible strategic shareholder for stepping up in a tough, volatile market and continuing to support and expand upon your large stake in Mydecine,” Bartch said. “This financing will give Mydecine the runway needed to continue meeting important milestones like launching our smoking cessation study in partnership with Johns Hopkins University and PTSD (Post Traumatic Stress Disorder) studies with various global military-focused organizations, furthering our drug development initiatives and growing paid subscribers on our telehealth platform Mindleap.” Bartch also underlined that he was proud of the company’s accomplishments to date and was looking forward to launching multiple clinical trials in early 2021. For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• Enhanced graphics, VR, AR, cryptocurrency expected to fuel fast-growing iGaming industry
• PLGNF leverages technological innovation to provide B2B solutions for operators that deliver an authentic experience
• PLGNF platform currently hosts 26 operators, eight in integration & user acceptance testing (“UAT”) stage
• iGaming growth expected to reach $127.3 billion by 2027, CAGR of 11.94 percent

Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF), a propriety SaaS technology company that delivers live dealer mobile technology to global online gaming operators, is on track to continue growing into 2022 by aligning with emerging technology trends outlined in a recent report (https://ibn.fm/raPVW). According to the report, technological innovation delivers enhanced graphics, virtual reality (“VR”), increased security, and cryptocurrency payment options that benefit the iGaming industry. PLGNF, with its proprietary cloud-based technology, offers operators turnkey solutions that leverage technological advancements to deliver authentic gaming experiences to a growing user base driven online by COVID-19 lockdown policies. Traditional games hosted in physical environments have mass appeal by blending visual and auditory elements that enhance the overall gaming experience. Today, technological innovation aims to duplicate that environment by replacing traditional games with RPG-themed versions, creating VR and AR environments, and offering live-dealer versions that deliver an element of social interaction to the iGaming experience. As a result, growth in iGaming is skyrocketing, projected to reach $127.3 billion by 2027 at a CAGR of 11.94 percent, according to Grandview Research (https://ibn.fm/jBZHB). Accordingly, as the industry grows, legislation is emerging with stricter rules that protect users, giving dozens of institutions and bodies the ability to regulate gambling platforms, issue licenses, and impose fines on operators engaging in malpractice. As a result, trust in the iGaming industry is expected to increase with expectations that enhanced regulation will attract more users to the platforms. PLGNF is in complete alignment with advancements in iGaming technology by providing a multitenant gateway that allows operators to deliver exciting gaming products on any device without sharing sensitive data or requiring an app store download. With 26 operators across four content aggregator clients in Europe and South Africa – and another eight operators at the UAT stage – the company’s cloud-powered platform is built to accommodate new demand easily. The company’s software is mobile-focused, device-agnostic, and built for one-handed play in portrait mode only. Current offerings include live-dealer table games broadcast from their state-of-the-art Las Vegas studio and a complimentary suite of eTable games based off their live versions. More games are in the development pipeline, with an expected release of an additional suite of games of both live and eTable versions in the near future, including craps, sicbo, hold ‘em poker, and 3-card poker. PLGNF is led by CEO Darcy Krogh – a pioneer in developing browser-based digital content for the iGaming market. Krogh is joined by CPO Guido Ganschow, who brings 13 years of experience creating real-time, live-dealer technology and platforms. Together they are joined by COO Steve Baker, a former executive of Shaw Communications who grew revenue from $300 million to $2.8 billion during his tenure as VP at the company (https://ibn.fm/2uhx6). With more than three decades of iGaming experience and multiple successful exits, PLGNF’s management team is positioning the company to lead the hyper-growth iGaming market with a mix of strategy, value, and alignment with technological innovation. For more information, visit the company’s website at www.Playgon.com. NOTE TO INVESTORS: The latest news and updates relating to PLGNF are available in the company’s newsroom at https://ibn.fm/PLGNF